Market cap
₹1,719 Cr
Market cap
₹1,719 Cr
Revenue (TTM)
₹462 Cr
P/E Ratio
30.4
P/B Ratio
5.6
Div. Yield
0 %
Quality Score
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
₹57 Cr
ROE
16.4 %
ROCE
18.4 %
Industry P/E
29.38
EV/EBITDA
16.6
Debt to Equity
0.4
Book Value
₹294.2
EPS
₹55.1
Face value
10
Shares outstanding
10,376,198
CFO
₹245.01 Cr
EBITDA
₹463.40 Cr
Net Profit
₹242.27 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Kwality Pharma
| -- | -- | -- | -- | -- | -- | -- |
|
BSE Healthcare
| 4.2 | 9.4 | 7.1 | 7.8 | 25.2 | 13.8 | 11.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Kwality Pharma
|
1,656.7 | 1,719.3 | 461.7 | 56.5 | 18.6 | 20.6 | 30.4 | 5.6 |
| 2,900.7 | 36,283.2 | 5,201.6 | 1,014.6 | 22.9 | 25 | 35.8 | 7.9 | |
| 8,046.0 | 20,116.4 | 2,177.5 | 200.9 | 11.3 | 26.5 | 100.1 | 24.2 | |
| 1,736.3 | 13,194.9 | 2,089.5 | 622.0 | 31.3 | 20.4 | 21.5 | 4.0 | |
| 1,353.6 | 18,759.4 | 3,078.2 | 469.4 | 26.4 | 14.9 | 43.5 | 5.2 | |
| 2,082.1 | 33,372.9 | 4,193.0 | 753.8 | 22.7 | 20.8 | 44.3 | 8.3 | |
| 4,679.0 | 21,426.9 | 2,482.3 | 853.6 | 33.7 | 18.9 | 25.1 | 5.4 | |
| 5,151.0 | 8,549.1 | 1,348.5 | 293.5 | 28.1 | 50.7 | 29.1 | 12.3 | |
| 418.7 | 8,189.0 | 1,432.0 | 149.0 | 19.1 | 7.9 | 54.6 | 3.3 | |
| 1,031.5 | 9,507.2 | 4,725.6 | 528.7 | 14.9 | 20.7 | 18.6 | 3.2 |
No Review & Analysis are available.
Manufacture of pharmaceuticals, medicinal chemical and botanical products
Incorporated
1983
Chairman
--
Managing Director
Ramesh Kumar
Headquarters
Amritsar, Punjab
Website
Looking for more details about Kwality Pharmaceuticals Ltd.’s IPO? Explore our IPO Details page.
Annual Reports
The share price of Kwality Pharmaceuticals Ltd is ₹1,656.70 (NSE) and ₹1,657.00 (BSE) as of 04-May-2026 IST. Kwality Pharmaceuticals Ltd has given a return of --% in the last 1 years.
The P/E ratio of Kwality Pharmaceuticals Ltd is 30.41 times as on 04-May-2026, a 4 premium to its peers’ median range of 29.38 times.
The P/B ratio of Kwality Pharmaceuticals Ltd is 5.63 times as on 04-May-2026, a 22 premium to its peers’ median range of 4.62 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
22.63
|
3.43
|
|
2024
|
17.85
|
1.90
|
|
2023
|
16.47
|
1.60
|
|
2022
|
5.02
|
3.34
|
|
2021
|
3.84
|
0.96
|
The 52-week high and low of Kwality Pharmaceuticals Ltd are Rs 1,737.45 and Rs 1,561.00 as of 04-May-2026.
Kwality Pharmaceuticals Ltd has a market capitalisation of ₹ 1,719 Cr as on 04-May-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Kwality Pharmaceuticals Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.